Serotiny designs novel multi-domain proteins for enhanced control of cell and gene therapies.
Investors 2
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | MBC BioLab... | mbcbiolabs... |
Mentions in press and media 2
| Date | Title | Description |
| 06.06.2022 | Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains | The collaboration will utilize the Serotiny platform to design, analyze, evaluate, and screen Multi-Domain Protein libraries aiming to identify novel Chimeric Antigen Receptors (CAR) signaling domains SOUTH SAN FRANCISCO, Calif.–(BUSINESS W... |
| 28.02.2022 | Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins | The collaboration will utilize the Serotiny platform to engineer, analyze, score, and screen Multi-Domain Protein libraries aiming to identify and optimize Tessera’s novel programmable Gene Writer proteins SAN FRANCISCO–(BUSINESS WIRE)–Febr... |